PATENT CLAIM ANALYSIS

Application Number: 15942587
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-02
Patent Classification: ["514", "04400A"]

Abstract:
The present application relates to nucleic acid compounds, compositions comprising same and methods of use thereof for treatment of various diseases, disorders and conditions. The compounds are preferably chemically synthesized and modified double-stranded nucleic acid molecules which down regulate expression of a p53 gene.

Claim (Index 37):
The molecule or the pharmaceutically acceptable salt of such molecule of  claim 29 , wherein the 5\u2032 cap z\u2033 or z\u2033 is present and is selected from the group consisting of an abasic ribose moiety, an abasic deoxyribose moiety, an inverted deoxyribose moiety, an inverted deoxyabasic moiety (idAb), amino-C6 moiety (AM-c6), C6-amino-pi, a non-nucleotide moiety, in particular 1,3-propanediol, mono(dihydrogen phosphate) i.e. C3, a mirror nucleotide, a 5,6,7,8-tetrahydro-2-naphthalene butyric phosphodiester (THNB), and a conjugate moiety, such as a vitamin moiety or a drug moiety.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 91.0
- Lexical Diversity: 1.26316
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14421845', '14426513', '13700942', '15433400', '13521033']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8451762914050618
- 35 USC 102 Novelty (BERT): 0.5899583106898699
- Combined Prediction Score: 0.8196544933335426
- Mean Citation Score: 425.007888
- Max Citation Score: 516.79877
- Similarity Product: 452.0644352013743

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test